| Bioactivity | TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM[1]. | ||||||||||||
| Target | IC50: 4.4 nM (Very late antigen-4) | ||||||||||||
| Name | TCS 2314 | ||||||||||||
| CAS | 317353-73-4 | ||||||||||||
| Formula | C28H34N4O6 | ||||||||||||
| Molar Mass | 522.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Muro F, et al. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J Med Chem. 2009 Dec 24;52( |